Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Apr-Jun;29(2):127-36.
doi: 10.20524/aog.2016.0004.

Use of biologics and chemotherapy in patients with inflammatory bowel diseases and cancer

Aranzazu Jauregui-Amezaga  1 , Séverine Vermeire  1 , Hans Prenen  1
Affiliations
Review

Use of biologics and chemotherapy in patients with inflammatory bowel diseases and cancer

Aranzazu Jauregui-Amezaga et al. Ann Gastroenterol. 2016 Apr-Jun.

Abstract

Patients with inflammatory bowel disease have an additional risk of developing cancer compared with the general population. This is due to local chronic inflammation that leads to the development of gastrointestinal cancers and the use of thiopurines, associated with a higher risk of lymphoproliferative disorders, skin cancers, or uterine cervical cancers. Similar to the general population, a previous history of cancer in inflammatory bowel disease patients increases the risk of developing a secondary cancer. Large studies have not shown an increased risk of cancer in patients treated with biologics. In this review we discuss the prevention and treatment of cancer in patients with inflammatory bowel disease.

Keywords: Crohn’s disease; anti-TNF; cancer; chemotherapy; ulcerative colitis.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: Séverine Vermeire received grant support from MSD, Abbvie and Takeda and has received speaker fees/consultancy for Abbvie, MSD, Takeda, Pfizer, Galapagos, Mundipharma, Cellgene, Hospira, Genentech/Roche, Shire, Ferring; Hans Prenen is a senior clinical investigator of the Belgian Foundation against Cancer

Figures

Figure 1
Figure 1
Surveillance colonoscopies. (A) Surveillance colonoscopies for detecting dysplasia and preventing colorectal carcinoma. (B) Management of visible lesions at endoscopy. A visible lesion with dysplasia should be completely resected, independently of the grade of dysplasia or the localization relative to the inflamed mucosal areas. In the absence of dysplasia in the surrounding mucosa, the patient should follow the standard surveillance program. If endoscopic resection is not possible or if dysplasia is found in the surrounding flat mucosa, proctocolectomy should be recommended [27-29] CRC, colorectal cancer; IBD, inflammatory bowel disease; PSC, primary sclerosing cholangitis
Figure 2
Figure 2
Small bowel adenocarcinoma. A 45-year-old male, with a 26-year duration ileal Crohn’s disease presented with subobstructive symptoms. At magnetic resonance imaging (MRI), severe wall thickening and ulcerative stenosis was observed. The patient underwent a laparoscopic right hemicolectomy and the pathology study of the resected segment revealed an ileal adenocarcinoma. (A) T1-weighted MRI sequence in coronal plane after administration of gadolinium. Severe wall thickening (1 cm) and presence of inflamed lymph nodes, without inflammatory signs in the surrounding tissue can be observed. (B) T2-weighted MRI sequence in coronal plane. Additionally, a reduction of the lumen with ulcerative stenosis can be observed. (C) 25x magnification pathology study. Residual ileal mucosa can be observed in the left lower corner. The rest of the picture shows the transition to the ileal tumor, composed by very irregular and atypical glands in a fibrous stroma. (D) 400x magnification pathology study. Tumor glands can be observed in the resected ileum. They have a very irregular shape and are composed by atypical cells with big hypercromatic overlapping nucleus and necrotic material in the gland
Figure 3
Figure 3
Adenocarcinoma of intestinal origin adjacent to end-ileostomy. An 80-year-old male diagnosed with Crohn’s disease for more than 50 years, and for which an end-ileostomy for 14 years presented an exophytic lesion at the left side of the ileostomy (arrow). Biopsy of the lesion showed adenocarcinoma of intestinal origin
See this image and copyright information in PMC

References

    1. Dignass A, Lindsay JO, Sturm A, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 2:Current management. J Crohns Colitis. 2012;6:991–1030. - PubMed
    1. Dignass A, Van Assche G, Lindsay JO, et al. The second European evidence-based Consensus on the diagnosis and management of Crohn’s disease:Current management. J Crohns Colitis. 2010;4:28–62. - PubMed
    1. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn’s disease:The ACCENT I randomised trial. Lancet. 2002;359:1541–1549. - PubMed
    1. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353:2462–2476. - PubMed
    1. Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease:The CLASSIC-I trial. Gastroenterology. 2006;130:323–332. - PubMed

LinkOut - more resources